Skip to main content
[Preprint]. 2024 Jun 9:2024.06.07.24308618. [Version 1] doi: 10.1101/2024.06.07.24308618

Figure 5. Survival outcomes following ICI in EC patients stratified by BMI across different molecular subtypes.

Figure 5.

Kaplan-Meier curves for (A) PFS and (B) OS in patients with CN-H/TP53abn EC following ICI treatment stratified by BMI. (Normal - BMI: 18.5 – 24.9 kg/m2 in blue; Overweight – BMI 25 – 29.9 kg/m2 in red; Obese – BMI > 30 kg/m2 in green) (n=256). Kaplan-Meier curves for (C) PFS and (D) OS in patients with CN-L/NSMP EC following ICI treatment stratified by BMI (n=81). Kaplan-Meir curves for (E) PFS and (F) OS in patients with MSI-H EC following ICI treatment stratified by BMI (n=97). The P values in the OS plots were calculated using a log-rank test. HRs and 95% CIs for overweight and obese patients were calculated using normal weight as a reference. BMI, body mass index; OS, overall survival; PFS, progression free survival; EC, endometrial cancer; ICI, immune checkpoint inhibitor; CN-H/TP53abnl, copy number-high/TP53abnormal; CN-L/NSMP, copy number-low/no specific molecular profile; MSI-H, microsatellite instability-high; HR, Hazard ratio; CI, confidence interval.